Journal article Open Access


Dr. K. Ramesh1*, Dr.M.Ganesh2, Dr. Suresh Kumar Packiriswamy3, G.Sridhar4

DCAT Export

<?xml version='1.0' encoding='utf-8'?>
<rdf:RDF xmlns:rdf="" xmlns:adms="" xmlns:cnt="" xmlns:dc="" xmlns:dct="" xmlns:dctype="" xmlns:dcat="" xmlns:duv="" xmlns:foaf="" xmlns:frapo="" xmlns:geo="" xmlns:gsp="" xmlns:locn="" xmlns:org="" xmlns:owl="" xmlns:prov="" xmlns:rdfs="" xmlns:schema="" xmlns:skos="" xmlns:vcard="" xmlns:wdrs="">
  <rdf:Description rdf:about="">
    <rdf:type rdf:resource=""/>
    <dct:type rdf:resource=""/>
    <dct:identifier rdf:datatype=""></dct:identifier>
    <foaf:page rdf:resource=""/>
        <rdf:type rdf:resource=""/>
        <foaf:name>Dr. K. Ramesh1*, Dr.M.Ganesh2, Dr. Suresh Kumar Packiriswamy3, G.Sridhar4</foaf:name>
        <foaf:givenName>Dr.M.Ganesh2, Dr. Suresh Kumar Packiriswamy3, G.Sridhar4</foaf:givenName>
        <foaf:familyName>Dr. K. Ramesh1*</foaf:familyName>
            <foaf:name>1Nova College of Pharmacy, Vegavaram, Jangareddygudem Mandal, West Godavari Dist, A P, India. 2St.Mary's College of Education, Sarpavaram, Kakinada, Andhra Pradesh, India. 3Nova College of Pharmacy, Vegavaram, Jangareddygudem Mandal, West Godavari Dist, Andhra Pradesh, India. 4Research Associate, Hetero Labs Ltd, Jeedimetla, Hyderabad.</foaf:name>
    <dct:issued rdf:datatype="">2019</dct:issued>
    <dcat:keyword>Osimertinib Mesylate, Particle Size, Disintegrant, Dissolution Profile.</dcat:keyword>
    <dct:issued rdf:datatype="">2019-04-02</dct:issued>
    <owl:sameAs rdf:resource=""/>
        <skos:notation rdf:datatype=""></skos:notation>
    <dct:isVersionOf rdf:resource=""/>
    <dct:isPartOf rdf:resource=""/>
    <dct:description>&lt;p&gt;Osimertinib mesylate is a kinase inhibitor, prescribed for the treatment of patients, who are diagnosed with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC). The Innovator of the product is AstraZeneca and its brand name in US and EU market is TAGRISSO&amp;reg; (Osimertinib) 40 mg and 80 mg film coated Tablets. The recommended dose is one 80 mg tablet once daily taken orally with or without a meal. Approximately, 80-90 % of lung cancer comprise NSCLC. Solubility of Osimertinib is known to be affected by pH, it belongs to BCS class-III molecule. The current work attempted to study the impact of both particle size of API and concentrations of disintegrant (L-HPC) on in vitro drug release profiles of Osimertinib from tablet dosage form in comparison to in vitro drug release profiles of corresponding Innovator product in US market. Based on the scientific discussion of TAGRISSO&amp;reg; in EU market, and to increase the flow properties of blend for compression into tablets, dry granulation method (by Roller compaction) was adopted. Assay and in vitro dissolution of the finished product was analysed by UV method. The obtained dissolution results suggested that 500 ml of pH 4.5 Acetate buffer at 25 rpm was found to be more discriminatory media than pH 6.8 Phosphate buffer and pH 1.3 (containing 0.2 % NaCl) and film coated tablets with input micronized API (&amp;lt;10&amp;mu;) has shown similar physical characteristics (hardness, disintegration time) and in vitro drug release profiles to that of Innovator product.&lt;/p&gt;</dct:description>
    <dct:accessRights rdf:resource=""/>
      <dct:RightsStatement rdf:about="info:eu-repo/semantics/openAccess">
        <rdfs:label>Open Access</rdfs:label>
          <dct:RightsStatement rdf:about="">
            <rdfs:label>Creative Commons Attribution 4.0 International</rdfs:label>
        <dcat:accessURL rdf:resource=""/>
All versions This version
Views 185186
Downloads 186186
Data volume 173.4 MB173.4 MB
Unique views 177178
Unique downloads 172172


Cite as